Pharmacological Advances in Opioid Therapy: A Review of the Role of Oliceridine in Pain Management

Kaye, Alan D.; Edinoff, Amber N.; Babin, Katherine C.; Hebert, Chance M.; Hardin, Justin L.; Cornett, Elyse M.; Kaye, Aaron J.; Kaye, Adam M.; Urman, Richard D.

doi:10.1007/s40122-021-00313-5

Cited by 7 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The consequences of classifying novel ligands as biased without either numerical justification of statistically significant bias or corroboration of bias data from different studies are now becoming evident in areas beyond the confines of in vitro cell signaling and in vivo animal studies. In the clinical literature there is continuing reference to these new μ-opioid receptor agonists as being advantageous to the patient on the basis of their G protein bias, thus implying to the medical community mechanisms of drug action, such as G protein bias, that may not be justified at this time (99)(100)(101)(102)(103). Therefore, a careful assessment is needed of where we are in terms of biased ligands at the μ-opioid receptor.…”

Section: Lessons To Be Learned From Biased Agonists At the μ-Opioid R...mentioning

confidence: 99%

Biased Agonism: Lessons from Studies of Opioid Receptor Agonists

Kelly

Conibear

Henderson

2023

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

In ligand bias different agonist drugs are thought to produce distinct signaling outputs when activating the same receptor. If these signaling outputs mediate therapeutic versus adverse drug effects, then agonists that selectively activate the therapeutic signaling pathway would be extremely beneficial. It has long been thought that μ-opioid receptor agonists that selectively activate G protein– over β-arrestin-dependent signaling pathways would produce effective analgesia without the adverse effects such as respiratory depression. However, more recent data indicate that most of the therapeutic and adverse effects of agonist-induced activation of the μ-opioid receptor are actually mediated by the G protein–dependent signaling pathway, and that a number of drugs described as G protein biased in fact may not be biased, but instead may be low-intrinsic-efficacy agonists. In this review we discuss the current state of the field of bias at the μ-opioid receptor and other opioid receptor subtypes. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 63 is January 2023. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

show abstract

Section: Lessons To Be Learned From Biased Agonists At the μ-Opioid R...mentioning

confidence: 99%

Biased Agonism: Lessons from Studies of Opioid Receptor Agonists

Kelly

Conibear

Henderson

2023

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

show abstract

“…La oliceridina es un agonista del nociceptor opioide µ, que forma parte de ligandos sesgados; es decir, activa preferentemente una vía de señalización intracelular sobre otra. Al estimular selectivamente el acoplamiento de la proteína G y regular a la baja el reclutamiento de la β-arrestina, disminuye el desarrollo de ORAEs, en especial la depresión respiratoria y la emesis [31,32].…”

Section: Discussionunclassified

Opioid-free anesthesia. Review of the technique and application in a case of a patient addicted to opiates.

Sofía Adonina Nicolás Aller,

Silvia Ferrer Cerón,

Elsa Gil Robles

et al. 2024

Revista Electrónica AnestesiaR

View full text Add to dashboard Cite

INTRODUCCIÓN: Los opiáceos tienen efectos indeseables conocidos: náuseas, vómitos, sedación, íleo, depresión respiratoria, hiperalgesia, tolerancia, dolor crónico postoperatorio, adicción… La anestesia libre de opiáceos se basa en utilizar Ketamina, Dexmedetomidina, Lidocaína y otros fármacos coadyuvantes como AINES, corticoides, magnesio, hipotensores, junto con bloqueos regionales manejados con anestésicos locales, para conseguir una anestesia multimodal que sustituya en lo posible a los opiáceos. MÉTODO: Presentamos un caso de un paciente adicto crónico a opiáceos, que fue sometido a una laparotomía para amputación abdómino-perineal. Se colocó inicialmente un catéter epidural lumbar por el que se administró Levobupivacaína 0,25% en bolos, durante el período intraoperatorio. Además, el paciente fue manejado exitosamente con el protocolo que describimos en el artículo, utilizando una mezcla de fármacos como analgesia preemptiva, antes de la incisión quirúrgica, con objeto de prevenir la sensibilización al dolor del SNC; consta de AINES, Dexametasona y sulfato magnésico. Posteriormente se administró durante la inducción y mantenimiento anestésico, una mezcla de Lidocaína, Dexmedetomidina y Ketamina, a dosis bajas, junto con las dosis habituales de Propofol y relajación con Rocuronio, RESULTADO: La OFA permitió un adecuado manejo anestésico, con estabilidad hemodinámica óptima y ningún efecto secundario reseñable. CONCLUSIÓN: La OFA es una alternativa muy adecuada en el manejo anestésico de pacientes adictos a opiáceos, consiguiéndose excelentes resultados. Se requiere una amplia familiarización del anestesiólogo con la farmacología de las diversas fórmulas empleadas, así como su protocolización. PALABRAS CLAVE: opioid- free anaesthesia, OFA, analgesia, surgery, adverse effect, pain, opioid disorder.

show abstract

“…Delineating what causes a receptor to be recycled or degraded is of great importance. For instance, a therapeutic strategy that favored central nervous system opioid receptor recycling over degradation has been sought after for some time [ 72 ]. In addition to phosphatase activity, ubiquitination and de-ubiquitination can contribute to this process as an ubiquitin-tagged protein will be targeted for degradation [ 73 ].…”

Section: Gpcr Signaling and Receptor Barcodingmentioning

confidence: 99%